Eisai will continue to focus on creating and delivering products to target disease. Credit: mkfilm/Shutterstock.com.

Eisai has signed an agreement for the divestiture of rights for Merislon and Myonal, two of its long-standing products in Japan, to Kaken Pharmaceutical.

The transaction is valued at Y3.8bn ($25.10m).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Merislon treats vertigo and equilibrium disturbances and Myonal is a muscle relaxant, which patients have used since their respective launches in 1969 and 1983.

The agreement stipulates that Eisai will complete the transfer of marketing capabilities by March 2025, followed by manufacturing and marketing approval transfer.

The deal will not impact Eisai’s consolidated financial forecast for 31 March 2024.

See Also:

The company stated: “Eisai has determined that divesting rights for these products to Kaken, which has strengths in the products’ disease areas, is the optimal choice to ensure they continue contributing to a greater number of patients.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Eisai will continue to focus on creating and delivering products to target diseases with higher unmet medical needs such as neurology, oncology and global health.

Kaken is a research and development-driven pharmaceutical company that focuses on orthopaedics and dermatology.

Earlier this month, Eisai received approval for the amyloid beta-directed antibody Leqembi (lecanemab-irmb) in China to treat mild cognitive impairment associated with Alzheimer’s disease (AD) and mild AD dementia.

Leqembi, developed in partnership with BioArctic, will be available in the region in the third quarter of 2024. The approval in China is based on the international Phase III Clarity AD study.

Eisai will be responsible for distribution and information provision through expert medical representatives.